Search the Newsreel

Collegium Pharmaceutical Inc. (COLL) Q4 2022 Earnings Report - Results, Call & Slides

This report details Collegium Pharmaceutical's (COLL) Q4 2022 earnings. The company reported actual EPS of $1.09, missing the consensus by less than $0.01, and actual revenue of $129.62 million, beating expectations by $4.40 million. The report includes details on the earnings announcement, an audio …

Did Artisan Partners’ Pushback on Diversification Just Shift Colliers’ (TSX:CIGI) Investment Narrative?

Earlier this week, Artisan Partners publicly questioned Colliers International Group's push into the global engineering and design industry and disclosed that it had reallocated capital to other opportunities, even as Colliers' core commercial real estate operations continued to perform well. This challenge from a …

What's Going On With Collective Mining Ltd Stock Tuesday?

Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

This article analyzes the Q1 performance of branded pharmaceutical stocks, highlighting Collegium Pharmaceutical as a key example. It discusses industry tailwinds like precision medicine and AI adoption, alongside headwinds such as regulatory scrutiny and patent cliffs. While Collegium Pharmaceutical's revenue beat expectations, its full-year …

Collegium Pharmaceutical Inc

This article provides a detailed revenue breakdown for Collegium Pharmaceutical Inc. (COLL) by business segment and geographical region. It highlights major product contributions like Nucynta IR, Belbuca, and Xtampza ER, and notes that all revenue is generated within the United States. Key financial metrics …

CollPlant Biotechnologies (CLGN) holders buy 1,764,706 shares plus new warrants

A Loewenbaum-led investor group and related entities have reported a combined beneficial holding of 3,518,237 Ordinary Shares in CollPlant Biotechnologies (CLGN), representing 18.6% of outstanding shares. The Loewenbaum 1992 Trust recently purchased 1,764,706 Ordinary Shares along with Series A and Series B Warrants. These …

Colliers International Group (TSX:CIGI) Faces Questions As An Undervalued Narrative Holds

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Artisan Partners recently exited its position in Colliers International Group (TSX:CIGI). The firm cited …

Colliers International Group (CIGI) Lost Appeal Over Strategic Diversification Concerns

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. …

Renaissance Technologies LLC Has $51.85 Million Position in Colliers International Group Inc. $CIGI

Renaissance Technologies LLC significantly increased its stake in Colliers International Group Inc. (CIGI) by 28.8% in Q1, bringing its total holding to 485,061 shares valued at $51.85 million. Despite several recent price target reductions from analysts, the company maintains a "Moderate Buy" consensus rating …

CLGN|Collplant Biotechnologies Ltd|Price:0.327|Chg%:+0.012

This article provides a comprehensive stock analysis of Collplant Biotechnologies Ltd (CLGN) from TradingKey. It highlights the company's healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Despite high institutional ownership and analyst …

Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Collegium Pharmaceutical Inc (COLL) focusing on its dividends and stock splits. It highlights that the company has not distributed any dividends over the past five years and contains current stock price information. The page aims to present historical …

Fifth Third Bancorp Acquires 28,913 Shares of Collegium Pharmaceutical, Inc. $COLL

Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and shareholder types. Key data includes top shareholders like BlackRock Institutional Trust Company and Eventide Asset Management, as well as a breakdown of institutional shareholding trends over several quarters. …

Collegium Pharmaceutical, Inc. Revenue Breakdown – FWB:354

The article details Collegium Pharmaceutical, Inc.'s revenue breakdown for the last year. The company generated 664.59 million EUR, with the Pharmaceutical segment being the top performer and the United States contributing the entirety of this revenue. This marks an increase from the previous year's …

Collegium Pharmaceutical Inc (COLL) Institutional Confidence

Collegium Pharmaceutical Inc (COLL) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 119.28%, a decrease of 6.89% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 4.53% of shares outstanding.

Grove Collaborative Holdings, Inc. Revenue Breakdown – NYSE:GROV

CNL|Collective Mining Ltd|Price:14.130|Chg%:+0.810

Colliers International Group Inc (CIGI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividends and stock splits for Colliers International Group Inc (CIGI), detailing payout amounts and key dates for each dividend distribution. It highlights that the company has distributed $45.50 million USD in dividends over the past five years. …

CIBC Maintains Colliers International Group(CIGI.US) With Buy Rating, Cuts Target Price to $130

CIBC has reiterated its Buy rating for Colliers International Group (CIGI.US) but has revised its price target downwards to $130 from the previous target. This adjustment reflects an updated valuation while maintaining a positive outlook on the company's stock.

CollPlant Biotechnologies Ltd. Revenue Breakdown – NASDAQ:CLGN

This article provides a revenue breakdown for CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), highlighting that the United States was the largest contributor to its revenue. The company recorded $2.18 million USD from the U.S. last year, an increase from $484,000 USD the previous year.

Colliers International Group Inc (CIGI) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Colliers International Group Inc (CIGI), highlighting its current earnings forecast score and analyst ratings. Based on 11 analysts, the stock has an average price target of $180.50 and is largely rated as "Buy." Key financial forecasts include …

Colliers International Group Inc. Revenue Breakdown – TSX:CIGI

Grove to Report Second Quarter 2026 Financial Results on August 6, 2026

Grove Collaborative Holdings, Inc. (NYSE: GROV) announced it will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will host an investor conference call and webcast on the same day at 5:00 PM ET to discuss …

CIGI|Colliers International Group Inc|Price:93.900|Chg%:-3.850

Colliers International Group Inc. (CIGI) has strong fundamentals and growth potential, making its valuation fairly valued within the Real Estate Operations industry. Despite recent good stock performance, technical indicators suggest a potential downward trend in the medium term, with the stock currently trading sideways …

Collegium's Aug. 6 results will be followed by an 8 a.m. webcast

Collegium Pharmaceutical (NASDAQ: COLL) announced it will report its second-quarter 2026 financial results before the U.S. market opens on Thursday, August 6, 2026. The company will also host a live conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can …

Colliers International Group (CIGI) Expected to Release Quarterly Earnings on Thursday

Colliers International Group (CIGI) is scheduled to release its Q2 2026 earnings before the market opens on Thursday, July 30th. Analysts are forecasting earnings of $1.74 per share on revenues of $1.4719 billion. The company’s previous quarter missed EPS and revenue estimates, but revenue …

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026. A live conference call and webcast will follow at 8:00 a.m. ET, accessible via phone or the company's website. Collegium …

Grove's Second-Quarter Results Are Due After Markets Close Aug. 6

Grove Collaborative Holdings, Inc. (NYSE: GROV) announced it will report its second-quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will also host an investor conference call and webcast to discuss these results at 5:00 PM ET / 2:00 …

A&G Real Estate Partners Appoints Andrew Jacobs to Lead Real Estate Sales Division

NEW YORK, July 21, 2026--(BUSINESS WIRE)--A&G Real Estate Partners, a national real estate advisory firm specializing in lease optimization, lease renegotiations, real estate sales, and strategic real estate solutions, today announced that Andrew Jacobs has joined the firm to lead its real estate sales …

CollPlant Biotechnologies (CLGN) completes $10.4M exempt private securities deal

CollPlant Biotechnologies Ltd. (CLGN) has completed an exempt private securities offering, raising $10.4 million under Rule 506(b) of Regulation D. The offering included equity, Series A and Series B warrants, and underlying ordinary shares. H.C. Wainwright & Co., LLC served as the placement agent, …

Collegium Pharmaceutical to relocate headquarters to Boston

Collegium Pharmaceutical Inc. announced its corporate headquarters will relocate to One Lincoln in downtown Boston during the first quarter of 2027. The biopharmaceutical company, currently based in Stoughton, Massachusetts, is valued at $1.17 billion and reported strong financial results for Q1 2026, exceeding earnings …

After More Than 20 Years, Collegium Plans Boston Headquarters Move

Collegium Pharmaceutical (Nasdaq: COLL) announced its relocation of corporate headquarters to One Lincoln in downtown Boston, scheduled for the first quarter of 2027. This move, reflecting the company's evolution as a diversified biopharmaceutical business, aims to embed Collegium within a major healthcare and life …

Van Berkom & Associates Inc. Buys New Position in Colliers International Group Inc. $CIGI

Van Berkom & Associates Inc. has acquired a new position in Colliers International Group Inc. (NASDAQ:CIGI), purchasing 41,351 shares valued at approximately $4.41 million. This makes them owners of about 0.08% of the company's stock. Other institutional investors have also shown interest, with firms …

Is Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up?

Collegium Pharmaceutical (COLL) is considered undervalued with a narrative fair value of $54.33 against its last close of $36.08. The assessment is based on steady earnings growth and resilient margins from its pain and ADHD portfolio, particularly the successful integration and growth of Jornay …

Colliers International Group | SCHEDULE 13D: Others

This article reports on a SCHEDULE 13D filing related to Colliers International Group. The filing is categorized under "Others," indicating the nature of the disclosure.

COLL5756983 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the Collegium Pharmaceutical, Inc. bond, COLL5756983, detailing its interest rate and payment schedule. The bond has a current coupon rate of 2.88%, with the next payment planned for August 17, 2026. It offers an overview of the …